

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM610992

| | |
|------------------------------|---|
| SUBMISSION TYPE: | CORRECTIVE ASSIGNMENT |
| NATURE OF CONVEYANCE: | Corrective Assignment to correct the schedule of trademark applications and registrations to be assigned to Akorn Operating Company LLC previously recorded on Reel 007101 Frame 0022. Assignor(s) hereby confirms the assignment of the trademark applications and registrations to Akorn Operating Company LLC. |

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|-------------------------------|----------|----------------|---|
| Akorn, Inc. | | 10/01/2020 | Corporation: DELAWARE |
| Advanced Vision Research, LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Hi-Tech Pharmacal Co., LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Akorn Animal Health, LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Clover Pharmaceuticals LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Akorn International S.A.R.L. | | 10/01/2020 | Private Limited Liability Company: LUXEMBOURG |
| Oak Pharmaceuticals, LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Inspire Pharmaceuticals, LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| VersaPharm LLC | | 10/01/2020 | Limited Liability Company: GEORGIA |

RECEIVING PARTY DATA

| | |
|------------------------|-------------------------------------|
| Name: | Akorn Operating Company LLC |
| Street Address: | 1925 W. Field Court |
| City: | Lake Forest |
| State/Country: | ILLINOIS |
| Postal Code: | 60045 |
| Entity Type: | Limited Liability Company: DELAWARE |

PROPERTY NUMBERS Total: 58

| Property Type | Number | Word Mark |
|-----------------------|----------|--------------------------|
| Serial Number: | 85114820 | ADVANCING THE NEW VISION |
| Serial Number: | 73652686 | AK-FLUOR |
| Serial Number: | 77589830 | AKORN |

CH \$1465.00 85114820

| Property Type | Number | Word Mark |
|----------------|----------|--|
| Serial Number: | 86937435 | AKORN |
| Serial Number: | 77012922 | AKTEN |
| Serial Number: | 75829828 | AKWA TEARS |
| Serial Number: | 72124870 | AMICAR |
| Serial Number: | 73815445 | ANASED |
| Serial Number: | 74628335 | BETIMOL |
| Serial Number: | 77492827 | BUTORPHIC |
| Serial Number: | 72221381 | CAPASTAT |
| Serial Number: | 85961915 | CONTROL THE UNCONTROLLABLE |
| Serial Number: | 74389373 | DIABETIC TUSSIN |
| Serial Number: | 86025876 | DIADERM |
| Serial Number: | 86773391 | EYE RX DIRECT |
| Serial Number: | 87007235 | FAST AND FIERCE RELIEF |
| Serial Number: | 72203731 | FLURESS |
| Serial Number: | 73652684 | GENTAK |
| Serial Number: | 85961910 | GROUNDING IN SCIENCE. PROVEN IN PRACTICE |
| Serial Number: | 75315149 | IC-GREEN |
| Serial Number: | 72190096 | INAPSINE |
| Serial Number: | 75825569 | INDIGO CARMINE |
| Serial Number: | 76308782 | INSPIRE |
| Serial Number: | 76309035 | INSPIRE |
| Serial Number: | 85121025 | JEFFREY P. GILBARD, MD |
| Serial Number: | 76052135 | MAGINEX |
| Serial Number: | 75576028 | MAG-OX 400 |
| Serial Number: | 87007233 | MASTER OF MAGNESIUM |
| Serial Number: | 86210334 | MULTI-BETIC |
| Serial Number: | 76178246 | MYOCHRYSSINE |
| Serial Number: | 85071559 | MYORISAN |
| Serial Number: | 71308321 | NEMBUTAL |
| Serial Number: | 85967253 | OSMO-CORRECTION |
| Serial Number: | 75839701 | PAREMYD |
| Serial Number: | 78329276 | PHARMACEUTICAL GRADE |
| Serial Number: | 85967251 | RESTORES EYES NATURAL BALANCE |
| Serial Number: | 78862364 | SINUS BUSTER |
| Serial Number: | 78850704 | SINUS BUSTER ALL NATURAL NASAL SPRAY |
| Serial Number: | 78459733 | STERILID |
| Serial Number: | 75572570 | T TAYLOR PHARMACEUTICALS AN AKORN COMPAN |
| Serial Number: | 75829829 | TEARS RENEWED |

| Property Type | Number | Word Mark |
|----------------|----------|---------------------------|
| Serial Number: | 88457133 | THERA TEARS |
| Serial Number: | 74615598 | THERATEARS |
| Serial Number: | 86260607 | THERAPY FOR YOUR EYES |
| Serial Number: | 87049747 | THERATEARS EXTRA |
| Serial Number: | 76427523 | THERATEARS |
| Serial Number: | 78459728 | THERATEARS STERILID |
| Serial Number: | 76548343 | TOLAZINE |
| Serial Number: | 86631044 | TYPE YOU |
| Serial Number: | 86966811 | TYPE YOU DIABETIC CARE |
| Serial Number: | 72450878 | URO-MAG |
| Serial Number: | 76269614 | VERSAPHARM INCORPORATED |
| Serial Number: | 76269637 | VERSAPHARM INCORPORATED X |
| Serial Number: | 74266573 | VETAKET |
| Serial Number: | 72081126 | VO SOL |
| Serial Number: | 73815446 | YOBINE |
| Serial Number: | 78660833 | ZOSTRIX |
| Serial Number: | 73576274 | ZOSTRIX |

CORRESPONDENCE DATA

Fax Number: 3128622200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3128622000

Email: rob.soneson@kirkland.com

Correspondent Name: ROB SONESON

Address Line 1: 300 N LASALLE

Address Line 2: KIRKLAND & ELLIS LLP

Address Line 4: CHICAGO, ILLINOIS 60654

ATTORNEY DOCKET NUMBER: 14581-66-RFS

NAME OF SUBMITTER: Rob Soneson

SIGNATURE: /rsoneson/

DATE SIGNED: 11/25/2020

Total Attachments: 18

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page1.tif

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page2.tif

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page3.tif

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page4.tif

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page5.tif

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page6.tif

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page7.tif

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page8.tif

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page9.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page10.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page11.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page12.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page13.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page14.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page15.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page16.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page17.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 Filing copy#page18.tif

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM605590

| | |
|------------------------------|--|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL |

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|-------------------------------|----------|----------------|---|
| Akorn, Inc. | | 10/01/2020 | Corporation: LOUISIANA |
| Advanced Vision Research, LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Hi-Tech Pharmacal Co., LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Akorn Animal Health, LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Clover Pharmaceuticals LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Akorn International S.À.R.L. | | 10/01/2020 | Private Limited Liability Company: LUXEMBOURG |
| Oak Pharmaceuticals, LLC | | 10/01/2020 | Limited Liability Company: DELAWARE |
| Inspire Pharmaceuticals, LLC | | 10/02/2020 | Limited Liability Company: DELAWARE |
| Versa Pharm LLC | | 10/01/2020 | Corporation: DELAWARE |

RECEIVING PARTY DATA

| | |
|------------------------|-------------------------------------|
| Name: | Akorn Operating Company LLC |
| Street Address: | 1925 W. Field Court |
| City: | Lake Forest |
| State/Country: | ILLINOIS |
| Postal Code: | 60045 |
| Entity Type: | Limited Liability Company: DELAWARE |

PROPERTY NUMBERS Total: 58

| Property Type | Number | Word Mark |
|-----------------------|----------|--------------------------|
| Serial Number: | 85114820 | ADVANCING THE NEW VISION |
| Serial Number: | 73652686 | AK-FLUOR |
| Serial Number: | 77589830 | AKORN |
| Serial Number: | 86937435 | AKORN |
| Serial Number: | 77012922 | AKTEN |
| Serial Number: | 75829828 | AKWA TEARS |
| Serial Number: | 72124870 | AMICAR |

TRADEMARK

| Property Type | Number | Word Mark |
|----------------|----------|--|
| Serial Number: | 73815445 | ANASED |
| Serial Number: | 74628335 | BETIMOL |
| Serial Number: | 77492827 | BUTORPHIC |
| Serial Number: | 72221381 | CAPASTAT |
| Serial Number: | 85961915 | CONTROL THE UNCONTROLLABLE |
| Serial Number: | 74389373 | DIABETIC TUSSIN |
| Serial Number: | 86025876 | DIADERM |
| Serial Number: | 86773391 | EYE RX DIRECT |
| Serial Number: | 87007235 | FAST AND FIERCE RELIEF |
| Serial Number: | 72203731 | FLURESS |
| Serial Number: | 73652684 | GENTAK |
| Serial Number: | 85961910 | GROUNDING IN SCIENCE. PROVEN IN PRACTICE |
| Serial Number: | 75315149 | IC-GREEN |
| Serial Number: | 72190096 | INAPSINE |
| Serial Number: | 75825569 | INDIGO CARMINE |
| Serial Number: | 76308782 | INSPIRE |
| Serial Number: | 76309035 | INSPIRE |
| Serial Number: | 85121025 | JEFFREY P. GILBARD, MD |
| Serial Number: | 76052135 | MAGINEX |
| Serial Number: | 75576028 | MAG-OX 400 |
| Serial Number: | 87007233 | MASTER OF MAGNESIUM |
| Serial Number: | 86210334 | MULTI-BETIC |
| Serial Number: | 76178246 | MYOCHRYSSINE |
| Serial Number: | 85071559 | MYORISAN |
| Serial Number: | 71308321 | NEMBUTAL |
| Serial Number: | 85967253 | OSMO-CORRECTION |
| Serial Number: | 75839701 | PAREMYD |
| Serial Number: | 78329276 | PHARMACEUTICAL GRADE |
| Serial Number: | 85967251 | RESTORES EYES NATURAL BALANCE |
| Serial Number: | 78862364 | SINUS BUSTER |
| Serial Number: | 78850704 | SINUS BUSTER ALL NATURAL NASAL SPRAY |
| Serial Number: | 78459733 | STERILID |
| Serial Number: | 75572570 | T TAYLOR PHARMACEUTICALS AN AKORN COMPAN |
| Serial Number: | 75829829 | TEARS RENEWED |
| Serial Number: | 88457133 | THERA TEARS |
| Serial Number: | 74615598 | THERATEARS |
| Serial Number: | 86260607 | THERAPY FOR YOUR EYES |
| Serial Number: | 87049747 | THERATEARS EXTRA |

| Property Type | Number | Word Mark |
|----------------|----------|---------------------------|
| Serial Number: | 76427523 | THERATEARS |
| Serial Number: | 78459728 | THERATEARS STERILID |
| Serial Number: | 76548343 | TOLAZINE |
| Serial Number: | 86631044 | TYPE YOU |
| Serial Number: | 86966811 | TYPE YOU DIABETIC CARE |
| Serial Number: | 72450878 | URO-MAG |
| Serial Number: | 76269614 | VERSAPHARM INCORPORATED |
| Serial Number: | 76269637 | VERSAPHARM INCORPORATED X |
| Serial Number: | 74266573 | VETAKET |
| Serial Number: | 72081126 | VO SOL |
| Serial Number: | 73815446 | YOBINE |
| Serial Number: | 78660833 | ZOSTRIX |
| Serial Number: | 73576274 | ZOSTRIX |

CORRESPONDENCE DATA

Fax Number: 3128622200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3128622000

Email: rob.soneson@kirkland.com

Correspondent Name: Rob Soneson

Address Line 1: 300 N LaSalle

Address Line 2: Kirkland & Ellis LLP

Address Line 4: Chicago, ILLINOIS 60654

ATTORNEY DOCKET NUMBER: 14581-66-RFS

NAME OF SUBMITTER: Rob Soneson

SIGNATURE: /rsoneson/

DATE SIGNED: 10/28/2020

Total Attachments: 14

- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page1.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page2.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page3.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page4.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page5.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page6.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page7.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page8.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page9.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page10.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page11.tif
- source=Exhibit C_ Omnibus Trademark Assignment Agreement (K&E draft 9-28-20)_(72078375_1)#page12.tif

TRADEMARK ASSIGNMENT AGREEMENT

This TRADEMARK ASSIGNMENT AGREEMENT is dated as of October 1, 2020 (this “**Assignment**”), and is by and between Akorn, Inc., Advanced Vision Research, LLC, Hi-Tech Pharmacal Co., LLC, Akorn Animal Health, LLC, Clover Pharmaceuticals LLC, Akorn International S.À.R.L., Oak Pharmaceuticals, LLC., Inspire Pharmaceuticals, LLC, and VersaPharm LLC (each, an “**Assignor**” and collectively, the “**Assignors**”) on the one hand, and Akorn Operating Company LLC (“**Assignee**”) on the other hand. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement (as defined below).

WHEREAS, Assignors are the owners of the trademark registrations and applications for which it is listed as the current owner of record on **Exhibit A** (collectively, the “**Assigned Trademarks**”);

WHEREAS, Assignors and Akorn Holdings Topco LLC (“**APA Purchaser**”) are parties to that certain Asset Purchase Agreement, dated as of May 20, 2020 (the “**Purchase Agreement**”), pursuant to which Purchaser agreed to purchase the Acquired Assets and agreed to assume the Assumed Liabilities from Sellers;

WHEREAS Assignors, Assignee, APA Purchaser, and certain other parties set forth on the signature pages thereto entered into that certain Implementation Agreement, dated as of the date hereof (the “**Implementation Agreement**”), providing for, among other things, (i) a G Reorganization Election and (ii) in order to implement the G Reorganization, an agreement among the parties thereto that, notwithstanding the provisions of the Purchase Agreement, on the date hereof (a) the Sellers will transfer, assign, convey, and deliver to Assignee all of the Sellers’ right, title and interest in the Acquired Assets, free and clear of all Encumbrances other than Permitted Encumbrances and (b) Assignee will assume from Sellers the Assumed Liabilities;

WHEREAS, in order to effectuate the transactions contemplated by the Purchase Agreement, as amended by the Implementation Agreement, and pursuant to the terms and conditions thereof, Assignors and Assignee are hereby effecting the sale, conveyance, assignment, and transfer of all of the Acquired Assets, which assets include the Assigned Trademarks; and

WHEREAS, this Assignment is being executed and delivered pursuant to Section 2.3(c) of the Purchase Agreement.

NOW, THEREFORE, in accordance with the Purchase Agreement, as amended by the Implementation Agreement, and in consideration of the premises and the mutual agreements and covenants set forth in this Assignment, the Purchase Agreement and the Implementation Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties hereby agree as follows:

1. Assignment. Each of the Assignors, subject to any encumbrances related to prior agreements, hereby irrevocably sells, conveys, transfers, assigns, and delivers to Assignee all of each Assignor’s worldwide right, title, and interest throughout the world in and to the Assigned Trademarks, together with that portion of such Assignor’s business connected with the use of and

symbolized by the Assigned Trademarks, and all past and present goodwill associated therewith or symbolized thereby, all common law rights thereto, all registrations that have been or may be granted thereon, all applications for registrations thereof, the right to claim priority in accordance with international treaties and conventions, the right to all income, royalties, damages, and payments hereafter due or payable with respect to the Assigned Trademarks, the right to register, prosecute, maintain, and defend the Assigned Trademarks before any public or private agency, office, or registrar, and all claims, causes of action, and rights to sue for past, present, and future infringement or unconsented use of the Assigned Trademarks. Each of the Assignors authorizes the Commissioner of Patents and Trademarks in the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign countries or multinational authorities, to record Assignee as the assignee of all of each Assignor's right, title, and interest in and to the Assigned Trademarks and to deliver to Assignee, and to Assignee's attorneys, agents, successors, or assigns, all official documents and communications.

2. Further Assurances. Assignor covenants and agrees that, at any time and from time to time upon the request of Assignee, Assignor shall provide any further necessary documentation and do all further acts reasonably requested by Assignee to confirm and perfect title in and to the Assigned Trademarks in Assignee, its successors, and assigns, at Assignee's sole cost and expense. If the Assignee is unable, after reasonable effort, to secure the Assignor's signature on any such documentation for any reason whatsoever, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as such Assignor's agent and attorney-in-fact, to act for and in such Assignor's behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution, issuance, and perfection of the Assigned Trademarks with the same legal force and effect as if executed by such Assignor. For the avoidance of doubt, all fees incurred in connection with any filings relating to the assignment of the Assigned Trademarks with the United States Patent and Trademark Office or any foreign equivalent thereof will be paid by Assignee.

3. No Third Party Beneficiaries. This Assignment is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein expressed or implied shall give or be construed to give to any person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.

4. Terms of Purchase Agreement; Conflicts. The scope, nature, and extent of the Acquired Assets are expressly set forth in the Purchase Agreement. Nothing contained herein changes, amends, modifies, extends, limits, or otherwise alters (nor shall this Assignment be deemed or construed as changing, amending, modifying, extending, limiting or altering) the terms or conditions of the Purchase Agreement, as amended by the Implementation Agreement, in any manner whatsoever. This instrument does not create or establish rights, liabilities, or obligations not otherwise created or existing under or pursuant to the Purchase Agreement, as amended by the Implementation Agreement. The parties hereto acknowledge and agree that the representations, warranties, covenants, agreements, and indemnities contained in the Purchase Agreement, as amended by the Implementation Agreement, will not be superseded hereby but will remain in full force and effect to the full extent provided therein. In the event of any conflict between the provisions of this Assignment (including the exhibits) and the provisions of the Purchase Agreement, as amended by the Implementation Agreement, (including the Schedules and

exhibits), the provisions of the Purchase Agreement, as amended by the Implementation Agreement, shall govern, supersede and control in all respects to the extent of such conflict.

5. Governing Law. This Assignment, the negotiation, execution or performance of this Assignment and any disputes arising under or related hereto (whether for breach of contract, tortious conduct, or otherwise) shall be governed and construed in accordance with the Laws of the State of Delaware, without reference to its conflicts of law principles.

6. Entire Agreement. This Assignment, and the exhibits annexed hereto, and the Purchase Agreement, as amended by the Implementation Agreement, and the other agreements, certificates, and other documents contemplated hereby and thereby constitute the entire understanding among the parties hereto with respect to the subject matter hereof and thereof, and supersede all other understandings and negotiations with respect thereto. The parties hereto agree to define their rights, liabilities, and obligations with respect to such understanding and the transactions contemplated hereby exclusively in contract pursuant to the express terms and provisions of this Assignment, and the parties hereto expressly disclaim that they are owed any duties or are entitled to any remedies not expressly set forth in this Assignment or the Purchase Agreement, as amended by the Implementation Agreement.


7. Counterparts. This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when each party hereto shall have received counterparts hereof signed by each of the other parties hereto. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .peg or similar attachment to electronic mail (any such delivery, an “**Electronic Delivery**”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute the original form of this Assignment and deliver such form to all other parties. No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties have duly executed this Assignment as of the date first written above.

ASSIGNORS:


AKORN, INC.

By: 

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel and Secretary


ADVANCED VISION RESEARCH, LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory


HI-TECH PHARMACAL CO., LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

AKORN ANIMAL HEALTH, LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

CLOVER PHARMACEUTICALS LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

AKORN INTERNATIONAL S.À.R.L.

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

OAK PHARMACEUTICALS, LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

INSPIRE PHARMACEUTICALS, LLC.

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

VERSAPHARM LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Authorized Signatory

ASSIGNEE:

AKORN OPERATING COMPANY LLC

By: *J. Bonaccorsi*

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel and Secretary

[SIGNATURE PAGE TO TRADEMARK ASSIGNMENT AGREEMENT]

TRADEMARK
REEL: 007169 FRAME: 0624

EXHIBIT A
Trademark Applications

| Title | Country | Application No. | Filing Date | Status | Assignor |
|------------|--------------------------|--------------------|-------------|---------|-------------------------------|
| AKORN | Albania (IR) | 1336041 | 9/12/2016 | Pending | Akorn, Inc. |
| AKORN | South Korea (IR) | 1336041 | 9/12/2016 | Pending | Akorn, Inc. |
| AKORN | Bangladesh | 202646 | 10/2/2016 | Pending | Akorn, Inc. |
| AKORN | Botswana | BW/M/2016/00839 | 9/27/2016 | Pending | Akorn, Inc. |
| AKORN | China (IR) | 1336041 | 9/12/2016 | Pending | Akorn, Inc. |
| AKORN | Ethiopia | FTM/8414/17 | 3/1/2017 | Pending | Akorn, Inc. |
| AKORN | Indonesia | D002016047722 | 10/6/2016 | Pending | Akorn, Inc. |
| AKORN | Kuwait | 183751 | 9/25/2016 | Pending | Akorn, Inc. |
| AKORN | Nigeria | F/TM/O/2016/109648 | 10/4/2016 | Pending | Akorn, Inc. |
| AKORN | Qatar | 110397 | 11/29/2016 | Pending | Akorn, Inc. |
| AKORN | South Africa | 2016/26761 | 9/19/2016 | Pending | Akorn, Inc. |
| AKORN | Sri Lanka | 211594 | 9/27/2016 | Pending | Akorn, Inc. |
| AKORN | Yemen | 77345 | 12/17/2016 | Pending | Akorn, Inc. |
| STERILJID | New Zealand | 1131346 | 10/1/2019 | Pending | Advanced Vision Research, LLC |
| THERATEARS | Norway (Int'l Reg.) | 1197342 | 1/21/2014 | Pending | Advanced Vision Research, LLC |
| THERATEARS | Singapore (Int'l Reg.) | 1197342 | 1/21/2014 | Pending | Advanced Vision Research, LLC |
| THERATEARS | South Africa | 2014/01774 | 1/21/2014 | Pending | Advanced Vision Research, LLC |
| THERATEARS | Switzerland (Int'l Reg.) | 1197342 | 1/21/2014 | Pending | Advanced Vision Research, LLC |
| AKORN | India | 3537421 | 9/12/2016 | Pending | Akorn, Inc. |
| AKORN | Nigeria | F/TM/O/2014/18707 | 6/18/2014 | Pending | Akorn Inc. |
| AK-BETAX | Nigeria | F/TM/O/2014/18595 | 6/16/2014 | Pending | Akorn Inc. |
| AK-BRIMON | Nigeria | F/TM/O/2014/18626 | 6/17/2014 | Pending | Akorn Inc. |
| AK-CMC | Nigeria | F/TM/O/2014/18706 | 6/18/2014 | Pending | Akorn Inc. |
| AK-CROMO | Nigeria | F/TM/O/2014/18630 | 6/17/2014 | Pending | Akorn Inc. |
| AK-DRAZINE | Nigeria | F/TM/O/2014/18625 | 6/17/2014 | Pending | Akorn Inc. |
| AK-KETOR | Nigeria | F/TM/O/2014/18622 | 6/17/2014 | Pending | Akorn Inc. |
| AK-LATAN | Nigeria | F/TM/O/2014/18623 | 6/17/2014 | Pending | Akorn Inc. |

| Title | Country | Application No. | Filing Date | Status | Assignor |
|---|---------|-------------------|-------------|---------|---------------------------------|
| AK-MELLO | Nigeria | F/TM/O/2014/18705 | 6/18/2014 | Pending | Akorn Inc. |
| AK-NAPHALIN | Nigeria | F/TM/O/2014/18704 | 6/18/2014 | Pending | Akorn Inc. |
| AK-NEO-P | Nigeria | F/TM/O/2014/18592 | 6/16/2014 | Pending | Akorn Inc. |
| AK-TEARS | Nigeria | F/TM/O/2014/18593 | 6/16/2014 | Pending | Akorn Inc. |
| AK-TIFEN | Nigeria | F/TM/O/2014/18578 | 6/16/2014 | Pending | Akorn Inc. |
| AKGENTA | Nigeria | F/TM/O/2014/18703 | 6/18/2014 | Pending | Akorn Inc. |
| AKORNAPH | Nigeria | F/TM/O/2015/70291 | 11/23/2015 | Pending | Akorn Inc. |
| AKORNBET | Nigeria | F/TM/O/2015/70285 | 11/23/2015 | Pending | Akorn Inc. |
| AKORNCROM | Nigeria | F/TM/O/2015/70288 | 11/23/2015 | Pending | Akorn Inc. |
| AKORNTTEARS | Nigeria | F/TM/O/2015/70292 | 11/23/2015 | Pending | Akorn Inc. |
| AKORNTENAC | Nigeria | F/TM/O/2015/70293 | 11/23/2015 | Pending | Akorn Inc. |
| AKORNTMOL | Nigeria | F/TM/O/2015/70286 | 11/23/2015 | Pending | Akorn Inc. |
| AKORNTIFEN | Nigeria | F/TM/O/2015/70287 | 11/23/2015 | Pending | Akorn Inc. |
| AKORNTRIX | Nigeria | F/TM/O/2015/70290 | 11/23/2015 | Pending | Akorn Inc. |
| AKORNROLAC | Nigeria | F/TM/O/2015/70294 | 11/23/2015 | Pending | Akorn Inc. |
| DESIGN ONLY | USA | 88/581,415 | 8/16/2019 | Pending | Advanced Vision Research, LLC |
| DETOMISED | USA | 88/677,127 | 11/1/2019 | Pending | Akorn Animal Health, LLC |
| MACUTRITION | USA | 88/164,134 | 10/22/2018 | Pending | Advanced Vision Research, LLC |
| PROPOSED | USA | 88/677,131 | 11/1/2019 | Pending | Akorn Animal Health, LLC |
| RESTORES + CLEANSSES + NOURISHES and Design | USA | 88/072,677 | 8/9/2018 | Pending | Advanced Vision Research, LLC |
| RESTORES EYES NATURAL BALANCE CLEANSSES EYELIDS AND LASHES NOURISHES EYES TO PROMOTE HEALTHY TEARS and Design | USA | 88/070,824 | 8/9/2018 | Pending | Advanced Vision Research, LLC |
| STERI-OPTICS | USA | 87/413,349 | 4/17/2017 | Pending | Hi-Tech Pharmaceutical Co., LLC |
| THERATEARS EXTRA | USA | 88/047,652 | 7/23/2018 | Pending | Advanced Vision Research, LLC |

Registered Trademarks

| Title | Country | Application No. | Registration No. | Assigner |
|--------------------------|------------------|------------------------|-------------------------|-----------------|
| ADVANCING THE NEW VISION | USA | 85114820 | 3954229 | Akom, Inc. |
| AK-FLUOR | USA | 73652686 | 1464246 | Akom, Inc. |
| AKORN | Algeria | 164287 | 99676 | Akom, Inc. |
| AKORN | Australia (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Bosnia (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Canada | 1792618 | TMA987817 | Akom, Inc. |
| AKORN | Costa Rica | 2016-0009676 | 261950 | Akom, Inc. |
| AKORN | EUTM (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Guatemala | 2016009653 | 229620 | Akom, Inc. |
| AKORN | Hong Kong | 303911643 | 303911643 | Akom, Inc. |
| AKORN | India (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Iceland (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Israel (IR) | 292976 | 292976 | Akom, Inc. |
| AKORN | Jordan | 149710 | 149710 | Akom, Inc. |
| AKORN | Kenya | 94117 | 94117 | Akom, Inc. |
| AKORN | Kosovo | KSM/2016/1311 | 21362 | Akom, Inc. |
| AKORN | Lebanon | N/A | 176515 | Akom, Inc. |
| AKORN | Macedonia (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Malaysia | 2016067189 | 2016067189 | Akom, Inc. |
| AKORN | Montenegro (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Nepal | 065274 | 2016/65274 | Akom, Inc. |
| AKORN | New Zealand (IR) | 1063094 | 1336041 | Akom, Inc. |
| AKORN | Norway (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Panama | 253351-01 | 253351-01 | Akom, Inc. |
| AKORN | Russia (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Saudi Arabia | 1437028411 | 1437028411 | Akom, Inc. |
| AKORN | Serbia (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Singapore (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Switzerland (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | Taiwan | 105056232 | 01856945 | Akom, Inc. |
| AKORN | Thailand | 160108644 | 191104966 | Akom, Inc. |
| AKORN | Turkey (IR) | 1336041 | 1336041 | Akom, Inc. |
| AKORN | UAE | 261898 | 261898 | Akom, Inc. |

| Title | Country | Application No. | Registration No. | Assignor |
|----------------------------|------------------------|-----------------|-------------------------------|---------------------------------|
| AKORN | Ukraine (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | United Kingdom (IR) | 1336041 | 1336041 | Akorn, Inc. |
| AKORN | Uruguay | 441,150 | 441,150 | Akorn, Inc. |
| AKORN | USA | 77589830 | 3,774,019 | Akorn, Inc. |
| AKORN | USA | 86937435 | 5,076,962 | Akorn, Inc. |
| AKTEN | Israel | 291476 | 291476 | Akorn, Inc. |
| AKTEN | USA | 77012922 | 3,631,872 | Akorn, Inc. |
| AKWA TEARS | USA | 75829828 | 2,429,583 | Akorn, Inc. |
| ALLERGY BUSTER | Canada | 1449252 | TMA/787366 | Hi-Tech Pharmaceutical Co., LLC |
| ALLERGY BUSTER & DESIGN | EU | 008506347 | 008506347 | Hi-Tech Pharmaceutical Co., LLC |
| AMICAR | USA | 72124870 | 729,648 | Clover Pharmaceuticals LLC |
| ANASED | Canada | 0878555 | TMA/526130 | Akorn Animal Health, LLC |
| ANASED | USA | 73815445 | 1,589,685 | Akorn Animal Health, LLC |
| BETIMOL | International Register | 728498 A | 728498 A | Akorn International S.A.R.L. |
| BETIMOL | USA | 74628335 | 1,961,729 | Akorn International S.A.R.L. |
| BETIMOL | USA | 79128616 | 4,442,019 (IR No. 728489A) | Akorn International S.A.R.L. |
| BUTORPHIC | USA | 77492827 | 3,648,627 | Akorn Animal Health, LLC |
| CAPASTAT | Canada | 0294218 | TMA/147966 | Akorn, Inc. |
| CAPASTAT | USA | 72221381 | 808,363 | Akorn, Inc. |
| CHOICE DM | Canada | 0821371 | TMA/535139 | Hi-Tech Pharmaceutical Co., LLC |
| CONTROL THE UNCONTROLLABLE | USA | 85961915 | 4,732,151 | Oak Pharmaceuticals, LLC |
| DIABETIC TUSSIN | USA | 74389373 | 1,861,344 | Hi-Tech Pharmaceutical Co., LLC |
| DIADERM | USA | 86025876 | 4,573,615 | Hi-Tech Pharmaceutical Co., LLC |
| EYE RX DIRECT (design) | USA | 86773391 | 5,296,978 | Akorn, Inc. |

| Title | Country | Application No. | Registration No. | Assignor |
|--|--------------------|-----------------|------------------|---------------------------------|
| FAST AND FIERCE RELIEF | USA | 87007235 | 5,355,854 | Hi-Tech Pharmaceutical Co., LLC |
| AKORN PHARMACAL, INC. | US State/Louisiana | N/A | 658495 | Hi-Tech Pharmaceutical Co., LLC |
| FLURESS | USA | 72203731 | 789,323 | Akorn, Inc. |
| GENT-AK | USA | 73652684 | 1,464,244 | Akorn, Inc. |
| GROUNDLED IN SCIENCE. PROVEN IN PRACTICE | USA | 85961910 | 4,748,523 | Oak Pharmaceuticals, LLC |
| HEADACHE BUSTER | Canada | 1449250 | TMAA787365 | Hi-Tech Pharmaceutical Co., LLC |
| IC-GREEN | Canada | 0855183 | TMAA531645 | Akorn, Inc. |
| IC-GREEN | Denmark | VA 003089 1997 | VR 199703234 | Akorn, Inc. |
| IC-GREEN | France | 97/684025 | 97/684025 | Akorn, Inc. |
| IC-GREEN | Germany | 39729824.2 | 39729824 | Akorn, Inc. |
| IC-GREEN | Italy | 362017000074996 | 362017000074996 | Akorn, Inc. |
| IC-GREEN | Switzerland | 4701/1997 | 447511 | Akorn, Inc. |
| IC-GREEN | USA | 75315149 | 2,189,196 | Akorn, Inc. |
| INAPSINE | USA | 72190096 | 783,911 | Akorn, Inc. |
| INDIGO CARMINE | USA | 75825569 | 2,389,845 | Akorn, Inc. |
| HYCILIA | Argentina | 3011174 | 2442900 | Inspire Pharmaceuticals, LLC |
| INSPIRE | USA | 76308782 | 2,578,523 | Inspire Pharmaceuticals, LLC |
| INSPIRE (& design) | USA | 76309035 | 2,578,526 | Inspire Pharmaceuticals, LLC |
| JEFFREY P. GILBARD, MD | USA | 85121025 | 4,556,180 | Advanced Vision Research, LLC |
| MAGINEX | Canada | 1083318 | TMAA641833 | Hi-Tech Pharmaceutical Co., LLC |
| MAGINEX | USA | 76052135 | 2,541,622 | Hi-Tech Pharmaceutical Co., LLC |
| MAG-OX 400 | USA | 75576028 | 2,633,768 | Hi-Tech Pharmaceutical Co., LLC |
| MASTER OF MAGNESIUM | USA | 87007233 | 5,355,853 | Hi-Tech Pharmaceutical Co., LLC |
| MULTI-BETIC | USA | 86210334 | 4,613,666 | Hi-Tech Pharmaceutical Co., LLC |

| Title | Country | Application No. | Registration No. | Assignor |
|---|-----------|-----------------|------------------|-------------------------------|
| MYOCHRYSINE | USA | 76178246 | 2,509,820 | Akorn, Inc. |
| MYORISAN | Canada | 1809727 | TMA1031869 | VersaPharm LLC |
| MYORISAN | USA | 85071559 | 4,199,023 | VersaPharm LLC |
| NEMBUTAL | Canada | 0181445 | UCA17215 | Oak Pharmaceuticals, LLC |
| NEMBUTAL | USA | 71308321 | 285,003 | Oak Pharmaceuticals, LLC |
| OSMO-CORRECTION | USA | 85967253 | 4,837,201 | Advanced Vision Research, LLC |
| PAREMYD | USA | 75839701 | 2,775,998 | Akorn, Inc. |
| PHARMACEUTICAL GRADE (& design) | USA | 78329276 | 3,272,765 | Hi-Tech Pharmacal Co., LLC |
| RESTORES EYES NATURAL BALANCE | USA | 85967251 | 4,846,473 | Advanced Vision Research, LLC |
| SINUS BUSTER | Canada | 1378181 | TMA733034 | Hi-Tech Pharmacal Co., LLC |
| SINUS BUSTER | USA | 78862364 | 3,194,160 | Hi-Tech Pharmacal Co., LLC |
| SINUS BUSTER ALL NATURAL NASAL SPRAY | USA | 78850704 | 3,503,088 | Hi-Tech Pharmacal Co., LLC |
| SINUS GENIE | Canada | 1378171 | TMA732672 | Hi-Tech Pharmacal Co., LLC |
| STERILID | Australia | 1064550 | 1064550 | Advanced Vision Research, LLC |
| STERILID | EU | 004549721 | 004549721 | Advanced Vision Research, LLC |
| STERILID | India | 1376561 | 1376561 | Advanced Vision Research, LLC |
| STERILID | Mexico | 731418 | 907,931 | Advanced Vision Research, LLC |
| STERILID | USA | 78459733 | 3,140,041 | Advanced Vision Research, LLC |
| T TAYLOR PHARMACEUTICALS AN AKORN COMPANY | USA | 75572570 | 2,340,300 | Akorn, Inc. |
| TEARS RENEWED | USA | 75829829 | 2,429,584 | Akorn, Inc. |
| THERA LID | Canada | 1387723 | TMA766,079 | Advanced Vision Research, LLC |
| THERA TEARS | EU | 002996155 | 002996155 | Advanced Vision Research, LLC |

| Title | Country | Application No. | Registration No. | Assignor |
|------------------------|------------------------|-----------------|------------------|-------------------------------|
| THERA TEARS | Mexico | 731417 | 902036 | Advanced Vision Research, LLC |
| THERA TEARS | USA | 88457133 | 5,943,133 | Advanced Vision Research, LLC |
| THERA TEARS | USA | 74615598 | 2,041,112 | Advanced Vision Research, LLC |
| THERAPY FOR YOUR EYES | USA | 86260607 | 4,843,058 | Advanced Vision Research, LLC |
| THERATEARS EXTRA | USA | 87049747 | 5,586,699 | Advanced Vision Research, LLC |
| THERATEARS | Australia | 730182 | 730182 | Advanced Vision Research, LLC |
| THERATEARS | Canada | 1085366 | TMA573256 | Advanced Vision Research, LLC |
| THERATEARS | Canada | 1153395 | TMA641310 | Advanced Vision Research, LLC |
| THERATEARS | EU | 002153476 | 002153476 | Advanced Vision Research, LLC |
| THERATEARS | Guatemala | 2014000962 | 201476 | Advanced Vision Research, LLC |
| THERATEARS | India | 1376560 | 1376560 | Advanced Vision Research, LLC |
| THERATEARS | International Register | 1197342 | 1197342 | Advanced Vision Research, LLC |
| THERATEARS | Lebanon | N/A | 155229 | Advanced Vision Research, LLC |
| THERATEARS | New Zealand | 274324 | 274324 | Advanced Vision Research, LLC |
| THERATEARS | USA | 76427523 | 2,770,188 | Advanced Vision Research, LLC |
| THERATEARS STERILID | USA | 78459728 | 3,181,614 | Advanced Vision Research, LLC |
| TOLAZINE | USA | 76548343 | 2,905,937 | Akorn Animal Health, LLC |
| TYPE YOU | Canada | 1728450 | TMA1040395 | Akorn, Inc. |
| TYPE YOU | USA | 86631044 | 5,291,486 | Akorn, Inc. |
| TYPE YOU DIABETIC CARE | Canada | 1776093 | TMA1047727 | Akorn, Inc. |
| TYPE YOU DIABETIC CARE | USA | 86966811 | 5,297,364 | Akorn, Inc. |

| Title | Country | Application No. | Registration No. | Assignor |
|------------------------------|--------------------|-----------------|------------------|-------------------------------|
| URO-MAG | USA | 72450878 | 974,841 | Hi-Tech Pharmacal Co., LLC |
| MYORISAN | Mexico | 1144174 | 1217500 | VersalPharm LLC |
| VERSAPHARM INCORPORATED | USA | 76269614 | 2,588,146 | VersalPharm LLC |
| VERSAPHARM INCORPORATED X | USA | 76269637 | 2,685,550 | VersalPharm LLC |
| AKORN PHARM, INC. | US State/Louisiana | N/A | 658517 | VersalPharm LLC |
| VETAKET | USA | 74266573 | 1,803,032 | Akorn Animal Health, LLC |
| VO SOL | USA | 72081126 | 696,678 | Hi-Tech Pharmacal Co., LLC |
| YOBINE | USA | 73815446 | 1,587,410 | Akorn Animal Health, LLC |
| ZOSTRIX | USA | 78660833 | 3,106,587 | Hi-Tech Pharmacal Co., LLC |
| ZOSTRIX | USA | 73576274 | 1,423,561 | Hi-Tech Pharmacal Co., LLC |
| THERATEARS | Kuwait | N/A | 130439 | Advanced Vision Research, LLC |

TRADEMARK

REEL: 007169 FRAME: 0632

RECORDED: 11/25/2020